CSHL 2023 Conference on Biology of Cancer: Microenvironment & Metastasis

CSHL 2023癌症生物学会议：微环境

• 批准号: 10750261
• 负责人: DAVID J. STEWART
• 金额: $ 1.5万
• 依托单位: COLD SPRING HARBOR LABORATORY
• 依托单位国家: 美国
• 财政年份: 2023
• 资助国家: 美国
• 起止时间: 2023-08-01 至 2024-07-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10750261
• 关键词: Archives; Area; Atmosphere; Biochemistry; Biological Models; Biophysics; Biotechnology; Cancer Biology; Cancer Control; Cell Communication; Cells; Cellular Metabolic Process; Cellular biology; Child; Child Care; Clinic; Collaborations; Communities; Consultations; Data; Development; Diagnostic; Disease; Disease Progression; Disease Resistance; Drug Industry; Ensure; Environment; Epigenetic Process; Europe; Faculty; Fostering; Friends; Funding; Genetic; Genotype; Goals; Heterogeneity; Hypoxia; Image; Immune; Immunologic Surveillance; Immunology; International; Investigation; Japan; Laboratories; Malignant Neoplasms; Medicine; Metabolic; Metabolism; Neighborhoods; Neoplasm Metastasis; New York; Non-Malignant; Oral; Organ; Participant; Peer Review; Persons; Phenotype; Physiology; Play; Postdoctoral Fellow; Process; Research; Research Institute; Research Personnel; Role; Scientist; Senior Scientist; Signal Transduction; Stromal Cells; Systems Biology; Therapeutic; Thinking; Tumor Biology; Tumor Cell Biology; Underrepresented Minority; Woman; Work; cancer cell; cancer initiation; cancer therapy; care systems; career; cell type; digital; drug development; graduate student; imaging modality; improved; interest; lectures; meetings; member; minority scientist; mouse model; neoplastic cell; new technology; next generation; novel therapeutic intervention; personalized cancer therapy; posters; prevent; response; role model; skills; social; success; symposium; therapy resistant; tumor; tumor heterogeneity; tumor microenvironment; tumorigenesis

Biology of Cancer: Microenvironment & Metastasis Cold Spring Harbor, New York September 19 – 23, 2023 ABSTRACT Cancer is now recognized as an abnormal organ where multiple cell types cooperate during cancer initiation and metastatic progression. Enormous progress has been made on identifying genetic, epigenetic and metabolic alterations in tumor cells and characterizing the different cell types composing a tumor, understanding the mechanisms by which these cell types interact with each other, developing ways to image the changes in a tumor and exploring therapeutic opportunities that take into account the non-malignant cells. Thus, there is an emergence of a need for an integrative approach for controlling cancer. However, most cancer meetings are organized to focus on one or two aspects of the many aspects of the biology of tumor. The proposed meeting takes an integrative approach to create a platform and bring together world leaders in different aspects of cancer biology, genetics, epigenetics, metabolism, signaling, immunology, diagnostics, and therapeutics to discuss the latest findings and promote dialogue aimed at solving the chief problems that prevent durable responses in the clinic. We believe that such an integrative approach will trigger discussions and interactions that cross the disciplinary borders and find new ways to develop and deliver novel therapeutic strategies for controlling cancer. The seventh rendition of this biennial conference will draw participants from academic labs, research institutes and biotech/pharmaceutical industries, and will include leaders in the field, established investigators, junior faculty, postdoctoral fellows, graduate students and corporate scientists. To ensure the presentation of the most cutting edge results many speakers will be chosen based on the quality of abstracts submitted to the meeting coordinators and session chairs several months prior to the meeting. Our emphasis will be on unpublished results. To maximize broad participation, efforts have been made to include outstanding women scientists and scientists from abroad as session chairs and invited speakers. Each session will be chaired by two leading scientists in the field selected by the organizers. Oral presentations will be selected from submitted abstracts by the session chairs in consultation with the organizers. Selected speakers will include graduate students, postdoctoral fellows and junior faculty aiming for maximal inclusion of young investigators. In addition, to promote recognition of the next generation of scientists, a late breaking session will be assembled with invited early career investigators to discuss exciting advances in cancer biology. Of special importance are the two poster sessions and panel discussion. The poster session provide an opportunity for many participants to present their work in an atmosphere conducive to informal discussion and the panel discussion engages thought leaders and the participants on one highly debated topic on the role played by personalized cancer medicine in improving cancer treatment. The meeting will be of moderate size and we expect about 300 people to attend, the vast majority of whom will be presenting a poster or talk.

癌症的生物学：微环境和转移 纽约冷春港 9月19日至23日，2023年 抽象的 癌症现在被认为是异常器官，其中多种细胞类型在期间合作 癌症的启动和转移进展。在识别方面取得了巨大进展 肿瘤细胞中的遗传，表观遗传和代谢改变并表征不同的细胞 组成肿瘤的类型，了解这些细胞类型相互作用的机制 彼此之间，开发方式来形象肿瘤的变化和探索疗法 考虑到非恶性细胞的机会。那是紧急的 需要一种控制癌症的综合方法。但是，大多数癌症会议是 组织的重点是肿瘤生物学许多方面的一个或两个方面。 拟议的会议采用一种综合方法来创建平台并将世界融合在一起 癌症生物学，遗传学，表观遗传学，代谢，信号，信号，信号，信号，信号，信号， 免疫学，诊断和疗法讨论最新发现并促进对话 旨在解决阻止诊所持久反应的主要问题。我们相信 这种综合方法将触发跨越学科的讨论和互动 边界并找到新的方法来制定和提供新颖的治疗策略来控制 癌症。 这两个年度会议的第七次演绎将吸引学术实验室的参与者， 研究机构和生物技术/制药行业，将包括该领域的领导者 成熟的研究人员，初级教师，博士后研究员，研究生和公司 科学家。为了确保呈现最前端的结果，许多演讲者将是 根据提交会议协调员和会议的摘要的质量选择 会议前几个月的主席。我们的重点将取决于未发表的结果。到 最大化广泛的参与，已努力包括杰出的女科学家 以及来自海外的科学家作为会议主席和邀请演讲者。每个会话将是 由组织者选择的两名领域的主要科学家主持。口头演示将 从会议椅与组织者协商的会议椅提交的摘要中选择。 选定的演讲者将包括研究生，博士后研究员和初级教师Aimy 为了最大程度地包括年轻的研究人员。此外，要促进对下一个的认可 科学家的一代，晚期会议将与受邀的早期职业组成 研究人员讨论癌症生物学的令人兴奋的进步。这两个特别重要的是 海报会议和小组讨论。海报会议为许多人提供了机会 参与者在氛围中介绍他们的作品，以进行非正式讨论和 小组讨论与思想领袖和参与者有关一个高度争论的主题 个性化癌症医学在改善癌症治疗方面所扮演的角色。会议 规模中等，我们希望大约300人参加，其中绝大多数 将介绍海报或谈话。